Table 2. NBS1 miscoding mutations identified in HCC and ICC.

Patient ID	Clinical parameters *	Age/sex	NBS1 mutation	Alteration in TP53 pathway
217	HCC/HBV(+)/Stage1/md	50/M	Codon 41, ATC→ATG, Ile→Met	TP53 mutation, P301L
				p14ARF deletion
375	HCC/HBV(+)/Stage1/wd	54/M	Codon 633, TCA→ACA, Ser→Thr	p14ARF promoter methylation
478	HCC/HBV(–)/Stage1/md	67/M	Codon 272, GAT→AAT, Asp→Asn	p14ARF promoter methylation
383	HCC/HBV(+)/Stage1/md	48/M	Codon 348, GTT→GAT, Val→Asp	TP53 mutation, Y220C
354	HCC/HBV(+)/Stage1/wd	46/M	Codon 415, AGT→AGA, Ser→Arg	MDM2 amplification
339	HCC/HBV(+)/Stage1/md	42/M	Codon 603, TTC→TTA, Phe→Leu	–
425	ICC/HBV(–)/Stage1/md	52/F	Codon 638, TCT→CCT, Ser→Pro	TP53 mutation, Q192H
				p14ARF promoter methylation
362	ICC/HBV(+)/Stage1/wd	38/M	Codon 90, ACT→TCT, Thr→Ser	p14ARF promoter methylation

^* HBV(+)/HBV(–): with/without hepatitis B virus infection; Stage 1/Stage1: tumor stage 1/>1; wd/md/pd: well/moderately/poorly differentiated.